Research and Development
Novel MOA Drug with Improved Efficacy and Convenient Usability
DR (Diabetic Retinopathy)
Our innovative research has led to the development of SMX, an eye drop formulation poised to revolutionize diabetic retinopathy treatment. Unlike current intraocular injections that offer limited efficacy and patient burden, SMX inhibits multiple angiogenic factors, offering a non-invasive, highly effective alternative.
AML (Acute Myeloid Leukemia)
We’re tackling AML with a dual-targeting approach that disrupts TRAP1 and mitochondrial membrane potential. Our therapies aim to overcome the resistance mechanisms that render standard treatments ineffective, offering new hope for those battling this aggressive cancer.
Target Disease: DR
Blocking pathologic angiogenesis by inhibiting HIF1 pathway
Intraocular Injection
Eye drop application
Pipeline
Our drug pipeline covers not only retinopathy and AML therapies but also diabetic complications and resistant solid tumors. We are also developing various formulations (oral, eye drop, and implant) to enhance efficacy and usability.
Current anti-VEGF DR drugs
Limited Efficacy
Inconvenient IVT injection
Our therapeutic drugs
Extended efficacy
Non-invasive application
